Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin vs Sitagliptin Add-on to Metformin in T2DM
NCT02949193Phase 3Completed
- Sponsor
- Dong-A ST
- Start
- May 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoint: Change in Glycated Hemoglobin at 24 weeks. Started May 2013; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02949193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949193.